November 10, 2025
Answering a question with a question; hope for a re-opening to end the shutdown which has continued 40 days, 6th weeks after 15 Democratic has voted NOT to reopen, becoming the longest in American history?
No one likes counting: 8 negative closes in the last 10 sessions with another week of earnings = positive moves
Earnings today: Voyager Therapeutics (VYGR)
News: Intellia Therapeutics (NTLA -$2.80 or -22.73% to $9.52 with a +0.91 Monday pre-open) stock crashed Friday, adding to 2 weeks of setbacks after a patient in its gene-editing study died following serious increases in liver enzymes. NTLA was testing its gene-editing process, nex-z, in patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy. In this condition, abnormal protein called transthyretin builds up on the heart and nerves, causing complications. NTLA had stopped dosing patients in the final-phase study after the patient was hospitalized.
Earnings this week: uniQure NV (QURE) and Capricor Therapeutics (CAPR) on 11/10, Precigen (PGEN) on 11/13
Pre-open Signals: 2 Negative and 6 Positive Indications
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
October 26, 2025
A sector catalyst
Novartis NVS) has agreed to buy Avidity Biosciences (RNA) closed up Friday +$0.60 or +1.24% to $49.15 for about $12 billion.
NVS will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Friday closing price.
Avidity Biosciences is a biopharmaceutical company. RNA is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). These AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies.
November 10, 2025
What did I write on Friday, “I’m still maintaining to BUY the dips …”
This a.m., I wrote: “No one likes counting: 8 negative closes in the last 10 sessions with another week of earnings = positive moves”
Pre-open Indication Scoring: 7 Hits and 1 Miss
RMi collects, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision
Never leave an investor uninformed!
October 26, 2025
A sector catalyst Novartis NVS) has agreed to buy Avidity Biosciences (RNA) closed up Friday +$0.60 or +1.24% to $49.15 for about $12 billion. NVS will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Friday closing price. Avidity Biosciences is a biopharmaceutical company. RNA is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). These AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies.
October 24, 2025
ADVM is up +$0.14 or +3.349% to $4.32 ADVM's lead program, Ixo-vec, is a P3 intravitreal gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Ixo-vec is designed as a single 1-time treatment to deliver continuous and stable intraocular aflibercept levels, thereby reducing the significant patient burden associated with current chronic anti-VEGF therapies, while also potentially leading to improved vision outcomes.
October 15, 2025
Who is pumping the volume thus the price, after the usual small and inching volume or no volume Challenging and questionable "aspects" state the obvious – a Ponzi Scheme! They’re BROKE filing with yet another PPM unfulfilled! What valuation model would even/ever justify a PPM pricing? Accumulated deficit to date= $103.2 M in 12 years WHO is their major shareholder – DST Capital and itsDAILY buyer, OTCQB: HRGN’s in-house fund run by its president Hong Yu, funded by Mrs. bin (Zhao) of Weston, Mass. ??? U.S. investors BEWARE, forewarned is forearmed?
3 hours 3 min ago
RMi Closing Bell: Almost Open
12 hours 54 min ago
RMi pre-open: A friendlier week and market?
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
